Abstract
Surufatinib is a novel small-molecule kinase inhibitor targeting VEGFRs, FGFR and CSF-1R. In two phase 3 randomized trials (NCT02588170 & NCT02589821) surufatinib demonstrated a manageable safety profile and statistically significant efficacy and was recently approved for the treatment of patients (pts) with epNET and pNET in China. Here, we performed this trial to investigate the efficacy and safety of surufatinib in patients with advanced NSCLC progressing after second-line or further treatment.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call